ArticleFrontiers in medicine2026
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schistosomal myelopathy (SM) is a rare and devastating neurological manifestation of schistosomiasis, predominantly affecting individuals in endemic regions. SM may present a wide range of positive and negative manifestations such as paresthesia, myalgia, low back pain, paraplegia and urinary dysfunction. Limited awareness and lack of access to supportive microbiological and imaging diagnostics means may delay clinical recognition. Methods: Case report of SM and a systematic review of the literature on its epidemiological patterns and clinico-radiological characteristics, including cases published from inception to April 27, 2025. Results: A 27-years-old man presented with chronic back pain, progressive paraparesis - modified Rankin 4, and urinary incontinence. Magnetic resonance imaging (MRI) revealed findings suggestive of inflammatory myelitis from T12 to L4, the cerebrospinal fluid (CSF) microscopy demonstrated the presence of Conclusion: Schistosomal myelopathy is a rare, aggressive neurological disorder primarily affecting young males. Even with appropriate medical therapy, a substantial proportion of patients remain functionally dependent (mRS ≥ 3). This emphasizes the critical importance of early recognition and prompt intervention to mitigate irreversible neurological impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.